Pulmonary arterial hypertension (PAH) is characterized by abnormal growth and enhanced glycolysis of pulmonary artery endothelial cells. However, the mechanisms underlying alterations in energy production have not been identified.
P
ulmonary arterial hypertension (PAH) is a rare disease characterized by profound vascular remodeling in the small peripheral arteries of the lung, leading to a progressive increase in pulmonary vascular resistance. 1 The consequence of pulmonary vascular obliteration is right-sided heart failure and increased mortality. 2 The classes of PAH include heritable PAH (HPAH), caused primarily by mutations in the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2), and an idiopathic form (IPAH), which resembles the inherited disease both clinically and at a molecular level. 3 Endothelial cell (EC) dysfunction is considered to be a critical initiating factor in the pathobiology of PAH, manifested by increased susceptibility to apoptosis and heightened permeability but also enhanced endothelial proliferation, contributing to the formation of plexiform lesions. 2 Recent studies have identified abnormalities in cellular bioenergetics in ECs isolated from patients with IPAH, associated with increased proliferation. Specifically, alterations in glucose uptake and utilization, accompanied by a reduction in mitochondrial oxidative phosphorylation, have been demonstrated, accompanied by similar findings in smooth muscle cells and fibroblasts from the hypertensive pulmonary vasculature. [4] [5] [6] [7] It is established that healthy ECs generate most of their energy from glycolysis. 8 It has been proposed that the reliance of ECs on glycolysis allows these cells to reduce oxygen consumption, thereby increasing the oxygen availability to perivascular tissues 9 and enabling ECs to adapt quickly to proangiogenic stimuli by providing more rapid ATP production than oxidative phosphorylation when shifting from a quiescent state to proliferation and migration. 8 Pulmonary artery ECs (PAECs) from patients with PAH exhibit a further shift to lactate synthesis and aerobic glycolysis, accompanied by reduced oxidative phosphorylation. 6, 7 This phenomenon, known as the Warburg effect, was originally observed in cancer cells and is considered necessary for the efficient allocation of nutrients between energy production and macromolecular biosynthesis in highly proliferative cells. 10 Despite the introduction of several vasodilator treatments, PAH remains a life-limiting disease, and existing therapies fail to target its underlying cellular and molecular abnormalities. 11 Thus, novel therapeutic approaches are urgently needed. Recent experimental approaches aimed at the normalization of glucose oxidation or the modulation of the balance between fatty acid oxidation and glucose oxidation have shown promise as therapies for PAH, confirming the importance of metabolic abnormalities in this disease. 12, 13 Restoring normal glycolysis in pulmonary vascular ECs might therefore represent a new and effective approach in the treatment of PAH.
MicroRNAs (miRNAs) are a class of small, noncoding RNAs that negatively regulate gene expression by targeting specific messenger RNAs (mRNAs) and inducing their degradation or translational repression. Several studies have confirmed the importance of miRNA-mediated gene regulation in cardiovascular development and pathology 14 and in metabolic abnormalities. 15 miRNAs are also involved in the pathobiology of PAH, 16 with effects on cell proliferation and apoptosis 17, 18 and mitochondrial metabolism. 19 Recently, a role for miR-124 was described in the proliferation of pulmonary artery smooth muscle cells and fibroblasts, 4, 20 linking decreased expression of miR-124 with the highly proliferative, migratory, and inflammatory phenotype of hypertensive pulmonary artery adventitial fibroblasts. 20 In the present study, consistent with previous reports in ECs derived from the hypertensive pulmonary artery, 6, 7 we confirmed the abnormal phenotype of blood outgrowth ECs (BOECs) derived from patients with PAH associated with enhanced glycolysis and reduced mitochondrial oxidative phosphorylation. Using unbiased miRNA and proteomic profiling, we identified miR-124 among the most downregulated miRNAs
Clinical Perspective
What Is New?
• Alterations in energy production have been critically involved in the abnormal cellular responses observed in pulmonary vascular cells from patients with pulmonary arterial hypertension (PAH).
• These include increased glucose uptake and utilization via glycolysis, accompanied by reduced mitochondrial oxidative phosphorylation.
• Mutations in the bone morphogenetic protein type 2 receptor (BMPR2), the commonest genetic cause of PAH, alter endothelial function, but the mechanisms are unclear.
• Here, we demonstrate that reduced expression of microRNA-124in PAH endothelial cells is responsible for the dysregulation of the splicing factor polypyrimidine tract binding protein and its target, pyruvate kinase M2, a major regulator of glycolysis, which contributes to abnormal cell proliferation.
• Reduced BMPR2 levels are associated with reduced microRNA-124 expression.
What Are the Clinical Implications?
• Correction of the dysregulated pathway linking microRNA-124, polypyrimidine tract binding protein, and pyruvate kinase M2 is sufficient to restore the normal glycolytic flux in PAH endothelial cells and to partially correct reduced mitochondrial activity, with a subsequent inhibition of the hyperproliferative phenotype characteristic of pulmonary vascular endothelial cells from patients with PAH.
• These findings provide new avenues for the treatment of PAH.
in BOECs from patients with HPAH and IPAH, associated with increased levels of a target protein, the splicing factor PTBP1 (polypyrimidine tract binding protein). We further show that upregulation of PTPB1 by decreased miR-124 expression, as reported in cancer cells, 21 contributes to the metabolic and proliferative abnormalities of PAH BOECs. The mechanism involved switching of expression between 2 pyruvate kinase muscle (PKM) isoforms, PKM1, normally expressed in adult cells, and PKM2, associated with hyperproliferative and hyperglycolytic cells. 22 Our experiments demonstrate a link between BMPR2 dysregulation and the expression levels of miR-124, PTBP1, and downstream targets, reaffirming a central role for BMPR-II in the development of PAH. Dysregulation of miR-124 and PTBP1 was also observed in the rat SUGEN-hypoxia model of severe PAH, supporting a conserved mechanism for glycolysis regulation between patients and experimental models of PAH. Notably, in vitro manipulation of miR-124 or PTBP1 restored normal glycolysis in ECs, partially restored mitochondrial tricarboxylic acid cycle activity, and corrected the hyperproliferative EC phenotype, suggesting that inhibition of this critical pathway could provide a promising new strategy in the treatment of PAH.
METHODS
A full description of the methods is presented in the onlineonly Data Supplement.
Cell Culture
BOECs were isolated and cultured as previously described. 23 Human PAECs were purchased from Lonza, Workingham, UK. Cells were maintained in complete EC growth medium-2 (EGM-2MV) and were used at passages 4 to 7. Human PAECs were derived from patients with IPAH or unused donor lungs. Clinical information on patients with PAH for PAEC and BOEC isolations is summarized in Table I in the online-only Data Supplement.
Measurement of Glycolytic Flux
Glycolytic flux of cells was measured by monitoring the conversion of H-glucose (PerkinElmer Life Sciences Inc, Boston, MA) to 3 H 2 O as previously described. 7 Briefly, 2×10 5 cells per well (BOECs from HPAH or healthy controls or control PAECs) were plated in a 48-well plate in normal medium (EGM-2 MV 10% FBS). At 24 hours after seeding (or 48-72 hours after transfection as indicated in the figure legends), H-glucose was added to a final concentration of 0.5 µCi/well (0.0185 MBq/well). Samples were incubated for 2 hours at 37°C in a humidified incubator under 5% CO 2 . Then, 200 µL/well of supernatant was collected and placed into glass vials containing hanging wells with filter paper soaked with H 2 O. Vials were capped, sealed with rubber stoppers, and incubated for 2 to 3 days at 37°C to reach equilibrium. During incubation, 3 H 2 O generated by glycolysis diffused from the bottom of the glass vials to the filter paper carried by the hanging wells through evaporation, condensation, and absorption. The filter paper was then transferred into scintillation vials containing 5 mL scintillation liquid and counted in a scintillation counter. Appropriate 3 H-glucose-only and H 2 O-only controls were included, enabling the calculation of H 2 O in each sample and thus the flux of glycolysis as described. 7 
Proliferation Assays
BOECs were maintained in complete EGM-2MV. Cells were plated in 24-well plates at 10 000 cells per well and then transfected with Silencer for PTBP1, an miR-124 Pre-miR miRNA Precursor, or a Pre-miR miRNA scramble negative control (Applied Biosystems, Foster City, CA) as described in the online-only Data Supplement. Cells were quiesced in serumfree medium for 4 hours and counted on days 0, 2, 5, and 7 with trypan blue exclusion.
SUGEN-Hypoxia Rat Model
Male Sprague-Dawley rats (12 weeks old; weight, 190-200 g) received a single injection of SUGEN-5416 on day 1 (20 mg/kg) and were then maintained in 10% O 2 for 3 weeks. Rats were returned to normoxia for a further 5 weeks. Right ventricular systolic pressure and right ventricular hypertrophy (ratio of right ventricular weight the left ventricular plus septal weight) were measured as described previously. 24 After death, lung tissue was harvested and frozen in liquid nitrogen. Protocols were conducted under the Animals (Scientific Procedures) Act 1986 (Amendment Regulations 2012) after ethics review by the University of Cambridge Animal Welfare and Ethical Review Body.
Statistical Analysis
Values are expressed as fold change or mean±SEM. Student t test, 1-way ANOVA, or 2-way ANOVA was used for statistical analysis, as specified in the figure legends. Differences with values of P<0.05 were considered statistically significant. For quantitative polymerase chain reaction (qPCR), samples were tested in triplicate, and data were analyzed with the Bonferroni post hoc test.
RESULTS

Mutation or Deficiency of BMPR2 Is Associated With Increased Glycolysis in ECs
To compare the metabolic profiles of control and HPAH BOECs, conditioned media (n=4 of each) were collected and analyzed on the Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry Platform (Metabolon Inc), as previously described. 25 Metabolic profiles of HPAH BOECs differed significantly from controls, as determined by multivariate analysis. In particular, hierarchical clustering analysis ( Figure IA Consistent with the metabolomic findings, glycolysis measured by 3 H-glucose metabolism was significantly higher in BOECs from patients with HPAH carrying a BMPR2 mutation ( Figure 1A ) and patients with IPAH ( Figure 1B ) compared with cells derived from control individuals. Lactate concentrations in cell supernatants were also higher in HPAH ( Figure 1C ) and IPAH (Figure 1D) . Because the expression level of BMPR2 is suppressed in pulmonary vascular cells of patients with PAH with nongenetic forms of PAH, 26 we measured glycolysis in control BOECs and PAECs after silencing of BMPR2 with siRNA or control siRNA. Seventy-two hours after transfection, glycolytic flux was significantly increased in siBMPR2-treated BOECs ( Figure 1E ) and PAECs ( Figure 1F ).
miRNA and Proteomic Screens Identify an Altered miR-124/PTBP1 Axis in PAH BOECs
To elucidate the molecular mechanisms by which loss of BMPR2 leads to altered endothelial glycolysis, we used an unbiased genome-wide screen to detect miRNAs dysregulated in BOECs derived from 4 patients with HPAH, 3 patients with IPAH, and 4 control subjects (Table I in the online-only Data Supplement). A total of 1066 miRNAs were measured by qPCR array. Seventeen miRNAs were altered in the principal comparison of HPAH versus control subjects (from −2.8-to 2.0-fold change; unadjusted P<0.05; Figure 2A and 2B and Table II in the online-only Data Supplement). Comparing miRNA levels in IPAH versus control BOECs revealed 34 altered miRNAs (from −3.2-to 3.6-fold change; Figure 2B and Table II in the online-only Data Supplement). Four miRNAs showed concordant changes in both HPAH and IPAH BOECs versus controls ( Figure 2C ). Of these, miR-124 exhibited the most pronounced and significant reduction (from −2.8-to −3.2-fold; P=0.006). Because of the modest sample size, these changes did not achieve statistical significance after a false discovery rate correction was applied ( Figure 2C and Table II in the online-only Data Supplement). However, several of the miRNAs identified were subsequently validated in larger sample sizes by qPCR analysis ( Figure II in the online-only Data Supplement). The reduction in miR-124 was further confirmed in BOECs from larger groups of patients with HPAH and IPAH (Table I in the online-only Data Supplement) and with a different qPCR platform ( Figure 2D and 2E). To determine whether BMPR-II is involved in the regulation of miR-124, we examined miR-124 expression after silencing of BMPR2 in control BOECs. miR-124 was significantly downregulated 24 and 48 hours after siRNA transfection, with miR-124 expression returning to baseline levels after 72 hours ( Figure 2F ).
In addition to miRNA profiling, we examined the proteome of HPAH BOECs compared with control cells using a highly quantitative multiplex proteomic approach based on labeling peptides from 8 different samples with 8 individual isobaric tags (iTRAQ), allow- 
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ing simultaneous assessment of relative and absolute changes 27 (Tables III and IV in the online-only Data Supplement). The ubiquitous RNA binding protein PTBP1, a known target of miR-124, 28 was among the most upregulated proteins (Table IV in the online-only Data Supplement). Although originally identified as a splicing factor, PTBP1 plays a central role in several cellular processes related to mRNA metabolism, including polyadenylation, mRNA stability, and translation initiation. 29 A comparison between the miRNA microarray and the proteomic study is provided in Table V in the online-only Data Supplement.
miR-124 and PTBP1 Are Aberrantly Expressed in PAH BOECs and Are Regulated by BMPR-II
The upregulation of PTBP1 in HPAH and IPAH BOECs was confirmed by qPCR and immunoblotting ( Figure 3A through 3F). In addition, immunohistochemistry in human lung tissue confirmed the localization of PTBP1 in the pulmonary vascular endothelium, with positive staining also observed in the adventitia ( Figure 3G ). To determine whether PTBP1 is linked to BMPR-II expression, we examined PTBP1 expression after siRNA si- A total of 1066 miRNAs were screened by quantitative polymerase chain reaction (qPCR) array in BOECs from 4 patients with heritable PAH (HPAH), 3 patients with idiopathic PAH (IPAH), and 4 control subjects. A, Volcano plot showing 17 miRNAs significantly altered (unadjusted P<0.05) between patients with HPAH and control subjects. B, Heat map showing relative expression patterns for the miRNAs altered in patients with HPAH and IPAH and the hierarchical clustering across all subjects. C, Four miRNAs were concordantly dysregulated in both groups of patients. Unadjusted P values, adjusted P values (false discovery rate [FDR]-adjusted P value), and fold change are shown. Note that the miRNA candidates identified in this screen did not pass typical FDR thresholds and therefore were prioritized on the basis of P values unadjusted for multiple comparisons. miR-124 expression was validated with 7 HPAH, 5 IPAH, and 8 control BOEC lines (D and E) to confirm the observations in the qPCR array. F, Control BOECs were transfected with an siBMPR2 and tested for miR-124 expression 24, 48, and 72 hours after transfection compared with transfection reagent alone (CTR) or scrambled siRNA (n=3). Data are presented as mean±SEM. Samples were tested in triplicate. Data were analyzed with an unpaired t test (D and E) or a 1-way ANOVA followed by Bonferroni post hoc test (F). ***P<0.001. *P<0.05.
lencing of BMPR2 in control BOECs and demonstrated increased expression of PTBP1 mRNA 72 hours after transfection ( Figure 3H ). Similarly, increased PTBP1 protein levels were observed 72 hours after transfection ( Figure 3I and 3J) .
Increased PTBP1 Regulates the Expression of the Glycolytic Factor PKM2
PTBP1 is a critical splicing factor determining the relative expression of pyruvate kinase isoforms PKM1 and PKM2, 30 which are major regulators of glycolysis. There- B and E, PTBP1 protein expression was determined in whole-cell lysates from 6 HPAH (B) and 6 IPAH (E) samples compared with 6 controls and normalized to β-actin expression. C and F, Quantitative densitometry analysis of the immunoblots shown in B and E, respectively. **P<0.01. G, PTBP1 localization was confirmed by immunostaining in lung tissue from patients with HPAH and nonaffected controls. Scale bars: 100 µm. Adv indicates adventitia; H&E, hematoxylin and eosin; and vWF, von Willebrand factor. H, PTBP1 gene expression was assessed by qPCR in control BOECs transfected with siBMPR2 or scrambled siRNA. Cells treated with the transfection reagent alone were used as a negative control (CTR). Total RNA was isolated 24, 48. and 72 hours after transfection. Data were analyzed with a 1-way ANOVA followed by Bonferroni post hoc test (n=3). ***P<0.001. I and J, Immunoblot analysis of PTBP1 expression 72 hours after transfection with siBMPR2 or scrambled siRNA. Nontransfected cells were used as a negative control. Expression was normalized to β-actin. J, Quantitative densitometry analysis of the immunoblot. Data were analyzed with an unpaired t test. *P<0.05. A and B, The expression of PKM2 was assessed by quantitative polymerase chain reaction (qPCR) in BOECs isolated from patients with heritable PAH (HPAH; A; n=7) or idiopathic PAH (IPAH; B; n=5) vs controls (n=8). Data were analyzed with an unpaired t test. ***P<0.001. **P<0.01. C, PKM2 localization and expression was confirmed by immunofluorescence labeling of PKM2 in HPAH BOECs and control samples (n=3). PKM2 is stained green; actin was counterstained with phalloidin (red); and nuclei were counterstained with DAPI (blue). Scale bars: 25 µm. WT indicates wild-type. D, PKM2 gene expression was assessed in control BOECs (n=3) transfected with siBMPR2 or scrambled siRNA control. Nontransfected cells were used as a negative control (CTR). Data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test (*P<0.05). E through I, Glycolytic factors MCT1 and LDHA were analyzed by qPCR in BOECs isolated from patients with HPAH (E and H; n=7) and IPAH (F and I; n=5) vs controls (n=8). Data were analyzed with an unpaired t test. ***P<0.001. **P<0.01. *P<0.05. G and J, siBMPR2-transfected control BOECs were analyzed for MCT1 (G) and LDHA (J) expression levels compared with scrambled control. Cells treated with the transfection reagent alone were used as a negative control. Data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test (n=3). Data are presented as the mean±SEM. Samples were tested in triplicate. *P<0.05.
fore, we determined the balance between PKM1 and PKM2 in ECs from patients with PAH. Using qPCR, we observed increased PKM2 expression in HPAH and IPAH BOECs compared with control cells (Figure 4A and 4B) . Conversely, the expression of PKM1 was reduced in HPAH and IPAH BOECs ( Figure III in the online-only Data Supplement). Notably, the expression of the precursor mRNA coding for both PKM1 and PKM2 did not differ between the groups, consistent with posttranscriptional regulation by PTBP1 ( Figure IVA and IVB in the onlineonly Data Supplement). Using confocal microscopy, we confirmed that PKM2 protein levels were increased in PAH cells, localized mainly to the perinuclear area of the cell, where PKM2 is known to interact with elements of the cytoskeleton and other glycolytic enzymes to form the glycolytic enzyme complex 31 ( Figure 4C ). To confirm a role for BMPR-II in the regulation of PKM2, we silenced BMPR2 in control BOECs and showed that PKM2 expression was significantly upregulated 72 hours after transfection ( Figure 4D ). Again, we observed no change in the expression of the precursor mRNA for both PKM1 and PKM2 ( Figure IVC in the online-only Data Supplement). We also measured the mRNA levels of 2 important glycolytic genes, monocarboxylate transporter 1 (MCT1) and lactate dehydrogenase A (LDHA). 32, 33 MCT1, a transporter that catalyzes the transport of lactate and pyruvate across the plasma membrane, is also a predicted target of miR-124. 34 LDHA catalyzes the final step of glycolysis, the interconversion of pyruvate and l-lactate. These experiments confirmed upregula- Figure 4E through 4J) .
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tion of MCT1 and LDHA in both HPAH and IPAH BOECs and in control BOECs 72 hours after BMPR2 siRNA knockdown (
Dysregulation of miR-124, PTBP1, and PKM2 in PAECs Derived From Patients With PAH
Although we and others have previously confirmed that BOECs are highly representative of ECs 23, 35, 36 and demonstrate the same abnormal cellular phenotypes reported in PAECs from patients with PAH, 23 we sought to confirm our observations in PAECs derived from patients with IPAH (Table I in the online-only Data Supplement). qPCR analysis confirmed the significant downregulation of miR-124 in PAH PAECs ( Figure 5A ), whereas immunoblotting confirmed increased expression of PTBP1 and PKM2 in IPAH samples ( Figure 5C-5E ). Moreover, immunofluorescence staining of remodeled pulmonary arteries demonstrated high expression levels of PTBP1 in endothelial and adventitial cells, whereas PTBP1 was undetectable in normal donor arteries ( Figure 5B ).
Supplementation of miR-124 in PAH BOECs Normalizes Expression of Glycolysis-Related Genes
We reasoned that restoration of miR-124 levels should normalize the expression of genes involved in the glycolytic program. Thus, we used an miR-124-specific mimic to show that 48 hours after miR-124 upregulation in HPAH BOECs, the expression of the glycolysis-related genes LDHA, pyruvate dehydrogenase kinase 1 and 2 (PDK1 and PDK2), and MCT1 was significantly reduced and partially restored and PKM1 expression was significantly increased ( Figure 6A through 6G) . Moreover, ex- A and C, Control (n=3; black bars) and heritable pulmonary arterial hypertension (HPAH; A; n=3; white bars) or idiopathic PAH (IPAH) blood outgrowth endothelial cells (BOECS; C; n=3; white bars) were transfected with an miR-124 mimic or siPTBP1, and glycolytic flux was measured after 48 hours and compared with untreated (CTR) or siScramble-treated cells. B and D, Lactate production was assessed in control and HPAH (B) or IPAH BOECs (D) treated in the same way as in A and C, respectively. E and F, Glycolysis was assessed in control BOECs (E; n=3) and pulmonary artery ECs (PAECs; F; n=3) transfected with siBMPR2, alone or in the presence of miR-124 mimic or siPTBP1, and compared with untreated (CTR) or siScramble-treated cells. G, Control BOECs (n=4) were transfected with siScramble (red line), and HPAH cells were transfected with an (Continued ) pression of PTBP1, PKM1, and PKM2 was comparable to levels in untreated control BOECs, suggesting that manipulation of miR-124 alone corrects the abnormal expression of glycolytic genes observed in PAH ECs (Figure 6A through 6C ). As expected, the expression of the precursor mRNA coding for both PKM1 and PKM2 did not change with the introduction of the miR-124 mimic ( Figure IVD in the online-only Data Supplement).
miR-124 Supplementation or PTBP1 Silencing Reverses the Hyperglycolytic Phenotype of PAH BOECs
To determine whether supplementation of miR-124 reverses the enhanced glycolysis observed in PAH BOECs, we measured the glycolytic flux of BMPR2-mutant HPAH, IPAH-derived, and control BOECs treated with an miR-124 mimic. Restoration of miR-124 levels reduced the flux of glycolysis in both PAH and control BOECs. Notably, glycolysis in mimic-treated HPAH and IPAH BOECs was comparable to the glycolytic flux of untreated and scramble-treated control cells ( Figure 7A and 7C) . Consistent with these findings, the increased lactate levels secreted from HPAH and IPAH BOECs returned to control levels after miR-124 supplementation ( Figure 7B and 7D) . miR-124 upregulation alone can therefore restore a normal glycolytic flux in PAH ECs.
To determine whether miR-124 affects glycolysis through the regulation of PTBP1, the effect of PTBP1 manipulation on glycolysis was evaluated in HPAH BOECs. HPAH, IPAH, and control BOECs were transfected with an siRNA against PTBP1, and the 3 H-glucose glycolytic flux was compared with untreated and scramble-treated BOECs. Silencing of PTBP1 decreased glycolysis in PAH and control ECs and restored a normal glycolytic flux in PAH cells ( Figure 7A and 7C) . The suppression of PTBP1 also corrected the increased lactate release from PAH BOECs ( Figure 7B and 7D) .
We next examined whether manipulation of miR-124 or PTBP1 could restore normal glycolysis after BMPR2 knockdown in control BOECs. Cells were cotransfected simultaneously with siBMPR2 and miR-124 mimic, siPTBP1, or a scrambled sequence as control. Both miR-124 upregulation and PTBP1 downregulation reversed the effect on glycolysis induced by BMPR2 silencing and restored glycolysis to normal levels ( Figure 7E ). Similar results were obtained in control PAECs ( Figure 7F ).
PKM2 Regulates LDHA Expression via Hypoxia Inducible Factor-1 Activity
Having shown that miR-124 augmentation restores LDHA levels in HPAH BOECs, we questioned whether this was the result of a direct effect of miR-124 on LDHA or mediated by the effect of miR-124 on PTBP1/ PKM2. Thus, we measured LDHA expression in HPAH BOECs transfected with siRNAs targeting PTBP1 or PKM2, 37 selecting an siRNA that robustly suppressed PKM2 expression without altering PKM1 levels ( Figure  VD and VE in the online-only Data Supplement). Silencing of PTBP1 or PKM2 restored LDHA expression to control levels ( Figure VA and VC in the online-only Data Supplement), suggesting that the effect of miR-124 on LDHA expression is mediated via PTBP1/PKM2. In addition, PKM2 can directly interact with the α subunit of the hypoxia inducible factor-1 (HIF1A), increasing HIF1 binding and transactivation of target genes, including LDHA, and PDK1. [38] [39] [40] To determine the role of HIF1, we measured LDHA and PDK1 expression in HPAH BOECs 48 hours after transfection with an HIF1A siRNA ( Figure  VH in the online-only Data Supplement). This experiment confirmed that HIF1 regulates LDHA and PDK1 expression in BOECs from patients with PAH ( Figure VF and VG in the online-only Data Supplement).
miR-124 and PTBP1 Manipulation Reverses the Hyperproliferative Phenotype of PAH BOECs
We investigated the effect of miR-124 and PTBP1 manipulation on proliferation of BOECs. HPAH BOECs were transfected with an miR-124 mimic or siPTBP1 and cultured for 7 days. Scramble-treated BMPR2-mutant and control BOECs were cultured under the same conditions for comparison. As expected, BMPR2-mutant BOECs treated with a scramble sequence demonstrated significantly higher growth rates by day 5, which was maintained at day 7, compared with control scrambletreated BOECs ( Figure 7G) . However, the transfection of miR-124 mimic restored cell proliferation to control levels, and PTBP1 knockdown induced an even greater inhibition of cell proliferation ( Figure 7G ). In addition to previously reported abnormalities in ECs derived from patients with PAH, we identified increased migratory capacity as a further phenotype of BMPR2-mutant ECs ( Figure VI in the online-only Data Supplement). 
miR-124 and PTBP1 Manipulation Partially Restores Mitochondrial Activity in PAH BOECs
Having shown that manipulation of miR-124 and PTBP1 reduces lactate production ( Figure 7B and 7D ) and partially corrects the expression level of PDK1 and PDK2 ( Figure 6E and 6F) , we evaluated the effect of miR-124 and PTBP1 manipulation on mitochondrial activity. Tricarboxylic acid cycle flux was measured in BMPR2-mutant BOECs treated with 14 C-glucose, and 14 C-CO 2 production was measured. Experiments were conducted in cells transfected with miR-124 mimic, siPTBP1, or scramble sequence. Scramble-treated control BOECs were also assessed to determine the basal flux of healthy cells. The experiment confirmed the reduced mitochondrial activity of untreated and scramble-treated BMPR2-mutant HPAH BOECs versus control cells and proved that the manipulation of miR-124 and PTBP1 can partially correct the reduced mitochondrial activity ( Figure 7H ).
BMPR-II Regulation of miR-124 Does Not Involve SMAD1/5 or Lim Kinase 1
Because BMPR-II regulates miR-124 expression, we explored potential mechanisms. siRNA silencing of the canonical downstream mediators of BMP signaling SMAD1 and SMAD5 did not affect expression of miR-124 or its downstream targets in control PAECs ( Figure  VIIA through VIID in the online-only Data Supplement). Alternative, noncanonical signaling downstream of BMPR-II includes interaction with a specific lim kinase (LIMK), LIMK1. 41 We therefore assessed the expression of miR-124 and its targets in control PAECs after the downregulation of LIMK1 with a specific siRNA and in control BOECs treated with an LIMK inhibitor, as previously reported. 42 These experiments failed to demonstrate an involvement of LIMK1 in the observed metabolic changes ( Figure VIIA through VIIH in the online-only Data Supplement).
miR-124 and Its Glycolytic Targets Are Dysregulated in Experimental PAH
We next questioned whether dysregulation of the miR-124/PTBP1/PKM2 axis occurs in the lungs of rats with experimental PAH. We measured the expression levels of miR-124 and glycolytic genes in the SUGENhypoxia rat model of PAH, characterized by severely elevated right ventricular systolic pressure and ratio of right ventricular weight to left ventricular plus septal weight 43 ( Figure 8A and 8B) and associated with increased glycolysis in pulmonary vascular cells. 44 Analysis of miR-124 expression in whole-lung mRNA from SU-GEN-hypoxia rats revealed downregulation of miR-124 compared with control animals ( Figure 8C ). In addition, the analysis of Ptbp1 gene and protein expression revealed upregulation in SUGEN-hypoxia rats, and Pkm2 gene expression was increased (Figure 8D through 8F) . Immunostaining for PTBP1 in lung tissue confirmed the expression of PTBP1 in the pulmonary endothelium and adventitia of hypertensive pulmonary arteries ( Figure 8G ). Mct1 and Ldha mRNA expression was also increased in the lungs of SUGEN-hypoxia rats, confirming the presence of a hyperglycolytic program of gene expression in this model ( Figure 8H and 8I) . SUGEN-hypoxia rats also demonstrated markedly reduced expression of lung Bmpr2 ( Figure 8J ).
DISCUSSION
The role played by altered cellular metabolism in the development of PAH is an area of intense interest. Systems biology approaches have revealed evidence of a profound alteration in energy production in cells isolated from the pulmonary vasculature of patients with PAH. 6, 7 Furthermore, expression arrays from Bmpr2 mutant mice indicate that nearly 50% of the significantly altered genes cluster in metabolic gene ontology groups, although specific metabolic pathways remain to be identified. 45 In PAH, ECs exhibit profound dysfunction. 2 Enhanced endothelial apoptosis and hyperproliferation together contribute to loss of small pulmonary arterioles and vascular occlusion. The presence of plexiform lesions in severe PAH represents an extreme example of disordered angiogenesis. 2 A central role of EC dysfunction in PAH is therefore well established. In addition, proliferation of pulmonary artery fibroblasts and smooth muscle cells also contributes to sustained vascular remodeling in established PAH. 2 Cellular metabolism is an important determinant of endothelial phenotype and function. 9 Despite the close proximity of ECs to circulating oxygen, these cells do not rely on oxidative metabolism but instead rely on glycolysis for >80% of their ATP requirements. 8 Moreover, glycolytic flux in ECs is further increased when switching from a quiescent state to a proliferative and migratory phenotype. This phenomenon has been reported previously in hyperproliferative ECs isolated from patients with IPAH. 6, 7 Of note, the introduction of BMPR-II mutations in pulmonary microvascular cells results in altered gene expression, 40% of which are related to metabolic pathways, 46 suggesting a mechanistic link between BMPR2 expression and metabolic dysfunction. Here, we confirm the presence of increased nucleotide levels in BOECs derived from patients with HPAH and IPAH, as well as increases in steady-state levels of glycolysis and glycolytic flux associated with increased proliferation. BOECs have been reported to be a readily accessible surrogate for PAECs, 23, 47 recapitulating the ORIGINAL RESEARCH ARTICLE same abnormalities observed in PAECs derived from patients with PAH in terms of increased cell proliferation, impaired network formation, and susceptibility to apoptosis. Such cells have the advantage of easy isolation from peripheral blood and the possibility to resample the same subject on multiple occasions. Here, we further demonstrate that BOECs isolated from patients with PAH with or without BMPR2 mutations also exhibit increased glycolysis and dysregulation of glycolytic genes comparable with PAECs isolated from patients. The main focus of this study was to identify potential mechanisms responsible for this hyperglycolytic phenotype and the potential involvement of BMPR-II in these changes, which has not been elucidated previously.
As part of an unbiased screen, we identified miR-124 as markedly suppressed in BOECs from patients with HPAH and IPAH. Interestingly, previous studies reported dysregulation of miR-124 in fibroblasts and smooth muscle cells from the hypertensive lung vasculature, 4, 20 which suggests a conserved and central role for this pathway in PAH. Our study is the first to link this finding with the metabolic alterations in ECs from patients with PAH. Abnormal miR-124 expression is documented in cancer cells, where it contributes to proliferation and invasion. 21 This miRNA also plays an essential role in neuronal development because overexpression of miR-124 promotes neuronal differentiation. 48 Here, we show that a direct target of miR-124, the splicing factor PTBP1, is responsible for the effect of this miRNA on the heightened glycolytic flux and hyperproliferation of ECs derived from patients with PAH.
PTBP1 is a ubiquitous RNA binding protein consisting of 4 RNA recognition motifs. 29 By binding to widely separated sequences on the same RNA molecule, PTBP1 induces a substantial restructuring of the target RNA and the introduction of RNA loops. Through this mechanism, PTBP1 is known to regulate not only RNA splicing but also RNA polyadenylation, translation, and stability. 29 PTBP1 is downregulated by the activity of miR-124, as previously described during neurogenesis. 28 Our findings further support a direct link between miR-124 and PTBP1 expression in the pulmonary vasculature and demonstrate how these changes perturb the glycolytic state of ECs.
PTBP1 is one of the main regulators of the enzyme pyruvate kinase, which plays a central role in glycolysis by catalyzing the dephosphorylation of phosphoenolpyruvate into pyruvate. Recently, it was reported in cancer cells that PTBP1 promotes the switching in expression of 2 forms of pyruvate kinase, PKM1 and PKM2, by suppressing PKM1-specific exon 9 inclusion and promoting PKM2-specific exon 10 inclusion. This results in increased aerobic glycolysis, consequently increasing cell proliferation. 28, 30 Pyruvate kinase has 4 isoforms produced from 2 distinct genes, which are expressed in an isoform-specific manner in tissues with different metabolic requirements. Among these, PKM1 is normally expressed in tissues where energy needs to be provided rapidly such as muscle and brain. In contrast, PKM2 is expressed mainly in the embryo and is progressively replaced by PKM1 in adult tissues. 22 However, when quiescent cells reenter the cell cycle, the tissue-specific isoenzymes are replaced by PKM2. Most tumors express mainly PKM2. 31 PKM2 is the preferential form expressed by hyperproliferative cells because of its ability to shift between a tetrameric highly active form that produces ATP efficiently and a dimeric form, which is much less active and less ATP-efficient but regulates the accumulation of glycolytic intermediates required for the synthesis of cell components needed by rapidly dividing cells 31 ( Figure VIII in the online-only Data Supplement). PKM2-specific exon 10 can also interact with HIF1A in the nucleus and function as a transcriptional coactivator for the expression of HIF targets (LDHA and PDK1 among others), promoting the shift from oxidative phosphorylation to glycolytic metabolism. 39 LDHA catalyzes the conversion of pyruvate into l-lactate, whereas the 4 PDK isoforms (PDK1-4) are responsible for the phosphorylation/inactivation of pyruvate dehydrogenase involved in the conversion of pyruvate into acetyl-CoA. Both of these enzymes can reduce the production of Acetyl-CoA, the main fuel for glucose oxidation, thus affecting mitochondrial respiration. Increased expression of PTBP1 shifts the balance of PKM isoforms toward PKM2, 28, 30 therefore inducing the downstream effects on growth and metabolism previously described. Only 1 study has previously demonstrated a direct link between miR-124, PTBP1, and PKM2 in the regulation of aerobic glycolysis. 49 We found that PKM2 and PTBP1 were increased in the lungs of rats with PAH induced by exposure to SUGEN-hypoxia, one of the most severe rodent models of PAH, associated with reduced expression of BMPR2 and miR-124. In vitro, miR-124 enhancement or PTBP1 silencing restored normal levels of PKM2 in PAH ECs. This was associated with restoration of normal glycolytic flux and inhibition of cell hyperproliferation. miR-124 dysregulation in PAH cells could therefore explain the sustained hyperproliferative phenotype of PAECs in culture. We also show that reduced expression of miR-124 is linked to widespread alterations in the expression of glycolytic enzymes, including MCT1, LDHA, PDK1, and PDK2, which were restored to basal levels by miR-124 enhancement. PTBP1, PKM2, and HIF1A siRNA silencing also restored basal expression levels of PDK1 and LDHA, suggesting that the shift from glucose oxidation to glycolysis in PAH BOECs is promoted partly by the recognized interaction between PKM2 and HIF1, responsible for HIF1 activation, and associated with a state of pseudohypoxia in these cells. 38, 39 Further studies are required to elucidate the precise mechanistic link between BMPR2 expression and glycolysis. We have established that the downregulation of BMPR2 leads to reduced expression of miR-124, increased expression of miR-124 targets, and increased glycolysis. However, the mechanism appears to be independent of canonical BMPR-II signaling via SMAD1/5 or noncanonical signaling via LIMK1. Further experiments are necessary to identify specific mechanisms by which BMPR2 regulates the expression of miR-124. Given that the penetrance of BMPR2 mutations is only 20% to 30% within families with PAH, it is possible that BMPR-II deficiency lowers the threshold for dysregulation of the miR-124/PTBP1/PKM axis, which can then be further critically reduced by additional environmental or genetic triggers for disease. More in-depth experiments are also required to determine whether the increase of mitochondrial respiration induced by miR-124 and PTBP1 manipulation is caused by increased production of acetyl-CoA after restoration of PDK1 and PDK2 expression or by mechanisms involving different miR-124/ PTBP1/HIF1 targets.
Although we provide compelling evidence that the miR-124/PTBP1/PKM2 axis is dysregulated in the pulmonary hypertensive lungs of SUGEN-hypoxia rats, a limitation of this study is the lack of an in vivo intervention to confirm that manipulation of this pathway is causally linked to the development of PAH. Such approaches would include the delivery of an miR-124 mimic to the pulmonary vasculature or the inhibition of PKM2 activity with agents such as shikonin. 50 In a linked article, Zhang et al 51 provide preliminary evidence that shikonin inhibits the metabolic reprogramming in the chronically hypoxic mouse lung, with a trend toward reduced right ventricular systolic pressures. Further optimization is required in preclinical models to determine whether manipulation of this pathway represents a viable approach for the clinic.
A further limitation of this study is the small sample of subjects used in the miRNA PCR array. The design of this experiment was constrained by the rarity of patient specimens and high costs. The miRNA candidates identified in the initial screen did not pass typical false discovery rate-corrected thresholds and therefore were prioritized on the basis of P values unadjusted for multiple comparisons. Thus, some of these candidates should be interpreted cautiously because we cannot exclude the possibility of false positives. Nevertheless, we independently confirmed significant changes in the levels of selected miRNAs in PAH cells by qPCR analysis using a larger sample size ( Figure II in the online-only Data Supplement). Moreover, we have demonstrated through extensive molecular, cellular, animal, and human data that miR-124 dysregulation plays a critical role in the pathobiology of PAH.
CONCLUSIONS
We provide evidence for a central role for reduced miR-124 in the heightened glycolysis of ECs derived from patients with PAH. Restoration of miR-124 levels in vitro restored normal expression of PTBP1, PKM2, and other glycolytic genes, which in turn reversed EC hyperproliferation, one of the most well-described phenotypes of PAH ECs. Similar dysregulation of the miR-124/PTBP1/ PKM2 axis has been shown to play a central role in the abnormal metabolic, proliferative, and inflammatory phenotype of pulmonary artery fibroblasts derived from patients with PAH and from calves with severe hypoxiainduced pulmonary hypertension. 51 Consistent with our observations, these authors confirm that manipulation of miR-124 or PTBP1 alone corrects the hyperglycolytic phenotype and increases mitochondrial respiration in pulmonary hypertensive fibroblasts. Taken together, these observations strongly suggest that the manipulation of the miR-124/PTBP1/PKM2 pathway represent a novel strategy to achieve additional benefits in the treatment of PAH by correcting the conserved metabolic phenotype of key cell types contributing to pulmonary vasculature remodeling. 
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